INTRODUCTION {#sec1-1}
============

Vitamin D is one of the fat-soluble vitamins, which has many functions in addition to its vital role in bone health, including prevention of cell proliferation in colorectal, prostate, and breast cancers and its role in prevention of autoimmune diseases.\[[@ref1]\] The need for vitamin D is higher in some stages of life, which include the rapid growth of the fetus in the embryonic stage, infancy, the early stage of childhood, puberty, and pregnancy.\[[@ref2][@ref3]\] Studies have shown that vitamin D deficiency is common in pregnancy\[[@ref4][@ref5]\] and is associated with increased incidence of preeclampsia,\[[@ref6]\] cesarean section (C/S),\[[@ref7]\] bacterial vaginosis,\[[@ref8]\] and gestational diabetes mellitus (GDM).\[[@ref9]\]

In addition, the reverse relationship between vitamin D concentration in serum and risk of diabetes type-II has been proved. Vitamin D has a direct effect on pancreatic beta cells and glucose metabolism, thus its level has a reverse relationship with glycosylated hemoglobin (HbA1C) levels.\[[@ref9]\] Vitamin D deficiency is known to be related to blood glucose and insulin concentration alteration and target tissue sensitivity to insulin.\[[@ref10]\] GDM is characterized by glucose intolerance in pregnancy and its pathophysiology is similar to type 2 diabetes mellitus, that is insulin tolerance and insulin insufficiency. On the other hand, GDM is associated with maternal (premature birth, infectious complications, hydramnios, hypertensive complications) and fetal (dead birth, altered fetus growth, metabolic disturbances, respiratory distress syndrome, obesity in childhood, and diabetes) complications.\[[@ref11]\] Vitamin D deficiency is common in pregnancy and evidence shows that vitamin D causes increased sensitivity to insulin and glucose tolerance, and many researchers have shown the relationship between vitamin D deficiency and GDM, but little is known about the effect of prescribing vitamin D supplementation in preventing gestational diabetes.\[[@ref12]\] Alzhime *et al*. in their study concluded that there is a relationship between vitamin D deficiency and gestational diabetes. They suggested that in order to investigate vitamin D prescription effects on gestational diabetes incidence, there is a need for intervention and prescribing vitamin D supplementation.\[[@ref13]\] Other studies have shown that vitamin D deficiency causes insufficient secretion of insulin and other pancreatic hormones and glucose intolerance in animal and human models.\[[@ref9]\]

Vitamin D deficiency and its effect on gestational diabetes have been investigated in various studies, however, the vitamin D dose needed for decreasing the risk of gestational diabetes is not known yet.\[[@ref14]\] Basic epidemiologic studies have shown a relationship between vitamin D deficiency and risk of gestational diabetes and diabetes type 2.\[[@ref15]\] Although observational studies have proved the relationship between vitamin D deficiency and increased risk of gestational diabetes,\[[@ref16]\] a reverse relationship has been identified between vitamin D deficiency and blood glucose in other studies.\[[@ref17][@ref18]\] *In vivo* studies on rats showed that vitamin D supplementation caused improved glucose tolerance and insulin secretion,\[[@ref19][@ref20]\] and in small trials vitamin D has caused blood glucose control in gestational diabetes.\[[@ref20][@ref21]\]

Considering the vitamin D deficiency in Iranian population, particularly in pregnant women, and its negative impact on pregnancy outcomes, the current study was designed to investigate the effect of vitamin D supplementation in the first and second trimesters on GDM in high-risk women.

MATERIALS AND METHODS {#sec1-2}
=====================

Study design and participants {#sec2-1}
-----------------------------

This study was a randomized double-blind controlled clinical trial that was carried out on 90 pregnant high-risk women in the first trimester with in the Obstetrics and Gynecology section of Be'sat hospital clinic offices in Sanandaj, Iran, in 2013. Sample size was calculated according to previous studies\[[@ref2][@ref3]\] considering the type one error rate α = 0.05, and statistical power 1-β = 0.9 for detecting a. At the beginning of the study, 110 participants were screened based on inclusion and exclusion criteria and 100 pregnant women were included and randomly divided into two groups using permuted block randomization of size two. The number of participants in each group was 50, but finally 46 and 44 participants per group remained in the analysis stage \[[Figure 1](#F1){ref-type="fig"}\]. Pregnant women with the following criteria were included; at least one risk factor for gestational diabetes including body mass index (BMI; kg/m^2^) more than 25, history of macrosome neonate, positive family history for diabetes and gestational diabetes, history of gestational diabetes in previous pregnancies, and glycosuria. Exclusion criteria were as follows: Chronic diseases including renal, rheumatologic, hepatic, thyroid; pregnant women who had had diabetes before pregnancy; gestational diabetes at the time of admission; history of consuming vitamin D and drugs that interfere with glucose metabolism. Blinding was carried out in which drugs and placebos were prepared to be completely similar in appearance and taste and put in numbered pockets based on a randomization, list and neither the patients nor the physician knew the trend. The protocol was approved by the Institutional Review Board (IRB) of Kordestan University of Medical Sciences and carried out in agreement with the Declaration of Helsinki and its subsequent revisions. After complete explanation of the study details, written informed consent was obtained from eligible patients and their legally authorized representatives, informing the participants of their rights to withdraw from the trial at any time without any interruption in their health care benefits. This trial was registered at the Iranian Clinical Trials Registry (IRCT number 14140742; [www.irct.ir](http://www.irct.ir)).

![Flow diagram of the trial](JRMS-21-2-g001){#F1}

Procedures and variables assessment {#sec2-2}
-----------------------------------

Then, randomization by simple randomization along with.

After entering the participants in the study, a glucose challenge test (GCT) was performed on all the patients in the first trimester. The women who were diagnosed with gestational diabetes were excluded from the study. Then, a blood sample was taken from women who had entered the study to measure the vitamin D level. Vitamin D level was determined in a laboratory by the Liebermann--Burchard method, in which the patient should fast for 12 h and not have a fatty dinner.

Women in the intervention group took vitamin D, 5000 units per week and women in the control group received placebo till the 26th week. Every month all the women were examined and their blood pressure were determined. GCT on the 26th week was carried out and gestational diabetes was determined.

Glucose tolerance test (GTT) was performed according to the following approach: Blood glucose was measured at baseline, then participants were given 75 g oral glucose, and blood glucose levels at 1 h and 2 h later were measured. The result for the glucose screening test was considered, as the fasting blood sugar was 100-120 mg/dL and 1 h after taking oral glucose equal or less than 140 mg/dL, while if blood glucose after 2 h was 140-200, it was considered to be impaired or positive GTT. Additionally, two impaired oral GTTs were considered as a positive test.\[[@ref15]\]

All the patients were followed up till delivery. Type of delivery, Apgar score, and macrosome neonate were determined.

Statistical analysis {#sec2-3}
--------------------

After collection the data were entered and analyzed using SPSS software. Quantitative data were expressed as mean (SD) and qualitative variables as frequency (percentage). Normality of quantitative data was evaluated using the Kolmogorov--Smirnov test and quantile-quantile (Q-Q) plot. Independent sample *t*-test was used for comparing normally distributed data between two groups, and chi-square or Fisher\'s exact test was used for comparing qualitative ones.

RESULTS {#sec1-3}
=======

[Table 1](#T1){ref-type="table"} presents the results of comparing the demographic and basic clinical variables between the two studied groups. Significant differences were found in two groups only in terms of educational levels (*P* \< 0.01) and history of diabetes (*P* \< 0.05), and the studied groups were similar based on other variables., residential place.

###### 

Demographic and basic baseline characteristics of study participants in two groups

![](JRMS-21-2-g002)

The results of our study showed that at the end of the study intervention period there was no significant difference between the two studied groups in terms of blood pressure and birth weight outcome (*P* \> 0.1) \[[Table 2](#T2){ref-type="table"}\]. In addition, no significant differences were observed before and after intervention in each groups in SBP and DBP (results not shown).

###### 

Results of comparing the SBP, DBP, and birth weight at end of study between the two study groups

![](JRMS-21-2-g003)

[Table 3](#T3){ref-type="table"} presents the results of comparing the main study\'s outcomes, i.e., the abnormality in GTT and GCT levels between the two groups. As can be seen, significantly higher percentages of positive GTT (34.8% vs 11.4%) and GCT (35.6% vs10.9%) were observed in the control group compared with participants in the vitamin D supplementation group; both *P* \< 0.01. Similar results were observed in stratified analysis based on the history of diabetes, in which the participants in the control group with and without history of diabetes experienced significant higher proportions of positive GTT and GCT than the intervention group (results not shown).

###### 

Main outcomes in intervention and control groups at the end of study

![](JRMS-21-2-g004)

DISCUSSION {#sec1-4}
==========

The current study was designed to investigate the effect of vitamin D supplementation in the first and second trimesters on GDM in high-risk women. Results showed that vitamin D supplementation in the first and second trimesters has an effect on GDM), in which significantly higher percentages of positive GTT (34.8% vs 11.4%) and GCT (35.6% vs 10.9%) were observed in the control group compared with participants in the vitamin D supplementation group; both *P* \< 0.01. Pregnancy consequences including macrosome neonate and increased C/S were not different in intervention and placebo groups.

Evidences show that vitamin D metabolism is related to diabetes incidence and its exacerbations. In most studies on pancreas *in vitro* or *in vivo*,\[[@ref22][@ref23][@ref24][@ref25]\] results have shown that there are vitamin D receptors and vitamin D~3~ binding proteins in pancreatic beta cells and in this way vitamin D can be influential in insulin secretion.\[[@ref25][@ref26][@ref27]\] Moreover, in studies on rats, vitamin D deficiency is associated with lower insulin secretion, and vitamin D supplementation therapy caused appropriate insulin secretion and improved glucose tolerance in these animals.\[[@ref25][@ref26][@ref27]\]

In a study by Lacroix *et al*.(2013)\[[@ref28]\] on low level of vitamin D in the first trimester and its relationship with increased gestational diabetes, results showed that women with lower vitamin D level were 1.48 times at higher risk for gestational diabetes than women who received vitamin D (*P* = 0.04), and our study results showed that pregnant women in the first trimester who received vitamin D had less GDM than women who received placebo, and this is statistically significant (*P* = 0.009).

In a cross-sectional study by Hoseinnejad *et al*.\[[@ref29]\] that was done on 741 pregnant women, after adjustment for BMI, a significant relationship was observed between insulin resistance index and insulin sensitivity index with vitamin D serum concentrations. They concluded that gestational diabetes prevalence is higher in pregnant women with vitamin D deficiency (less than 10 ng/L) than in women with a normal level of vitamin. Particularly in severe deficiency, accordingly sufficient levels of vitamin D can be effective in blood glucose control in pregnant women.\[[@ref28]\]

Asemi *et al*. investigated the effect of vitamin D and calcium on blood sugar control, inflammation, and oxidative stress in gestational diabetes in a clinical trial. Their results showed a significant reduction in plasma glucose tolerance and the insulin level in serum in comparison with the placebo group (*P* = 0.001).\[[@ref30]\] Inappropriate metabolism of insulin during gestational diabetes can cause complications in pregnancy such as macrosome neonate, trauma in birth, and preeclampsia.\[[@ref17][@ref31][@ref32]\] Asemi *et al*. also concluded that pregnancy outcomes such as neonate weight as well as C/S rate were not different between the intervention and placebo groups.\[[@ref30]\] Other studies showed that women who had received less vitamin D were at higher risk of gestational diabetes, which caused macrosome neonate and thus more C/S\[[@ref17]\] and more surgery risk as well as higher risk of type II diabetes.\[[@ref14]\] Evidence declares that neonates of women with gestational diabetes are at risk of glucose intolerance, obesity, and metabolic syndrome, which cause a higher risk of cardiovascular diseases in their children.\[[@ref15]\]

In a study by Farrant *et al*., the participants with vitamin deficiency received vitamin D and calcium supplementation at the 30th week; no association was found between vitamin D deficiency and gestational diabetes. However, it should be noted that this study was limited to women admitted to the hospital and its results could not be generalized to the whole population, and also, in line with our results, they did not find any relation with macrosome neonate.\[[@ref18]\]

Clinical trials in different part of world have shown that the effect of vitamin D supplementation in pregnant women increases birth weight and height.\[[@ref21][@ref33][@ref34][@ref35]\] However, in a study on Asian women living in England, no relation was demonstrated between vitamin D and birth weight.\[[@ref33]\] Different results in various trials can be attributed to the difference in supplementation period and levels of vitamin D in participants.

In a study by Rudnicki and Pedersen.\[[@ref21]\] the effect of vitamin D caused reduction of glucose tolerance in gestational diabetes, which was statistically significant. In other studies, reduction of OGT was not seen after vitamin D injection, while some other studies showed possible effects of vitamin D on glucose metabolism because of the effect of insulin secretion on beta cells.\[[@ref35][@ref36]\] Zhou *et al*.\[[@ref37]\] examined the effect of vitamin D on pregnancy outcomes, and their results showed that at the end of pregnancy, macrosome neonate, rate of C/S, birth weight, and congenital abnormalities were observed, consistent with our study\'s results; however, no decrease was observed in the Apgar score, while the prevalence of gestational diabetes and preterm delivery was higher in the group who had received higher levels of vitamin D than in women who had received low or moderate levels of vitamin D.\[[@ref37][@ref38]\]

The possible strengths of our study can be described as follows: This was the first study of high-risk pregnant women administered to vitamin D supplementation over the first two trimesters of pregnancy. Accordingly, it provides preliminary insight into the possible positive effects on gestational diabetes. On the other hand, the not-high patient compliance rate can be considered as a possible limitation. As there was the possibility for gynecology specialists to recommend patients to discontinue the drug, in order to prevent any misunderstanding, the purpose and procedure of the study were described to the specialists in a meeting.

CONCLUSION {#sec1-5}
==========

Our study showed that vitamin D supplementation for high-risk pregnant women in the first and second trimesters has an effective impact on gestational diabetes.
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